REG - Alliance Pharma PLC - Result of AGM

Alliance PharmaAnnouncement

29/07/2024 16:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240729:nRSc2665Ya&default-theme=true

RNS Number : 2665Y  Alliance Pharma PLC  29 July 2024

 For immediate release  29 July 2024

 

 

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Result of AGM

 

Alliance Pharma plc (AIM: APH), the international healthcare group, announces
that, at its Annual General Meeting held earlier today, all the resolutions
except resolutions 16 and 17, as set out in the Notice of Meeting, were duly
passed on a poll.

The number of the Group's shares in issue as at the date of the meeting was
540,565,539 ordinary shares of 1p each*.

The votes were as follows:

 

 RESOLUTION                                        VOTES FOR    %      VOTES AGAINST  %      VOTES WITHHELD
 1       Report and Accounts                       190,733,158  99.99  14,451         0.01   12,870
 2       Approve Remuneration Report               118,424,151  62.09  72,319,389     37.91  16,939
 3       Elect C. Pane                             167,821,883  99.34  1,108,987      0.66   21,829,609
 4       Elect R. McKenzie                         190,719,135  99.98  28,979         0.02   12,365
 5       Elect EL. Sjostedt                        190,672,019  99.96  76,095         0.040  12,365
 6       Elect N. Sedgwick                         190,708,640  99.98  38,979         0.020  12,860
 7       Re-elect A. Franklin                      190,546,663  99.89  201,451        0.11   12,365
 8       Re-elect J. Heper (Withdrawn)             -            -      -              -      -
 9       Re-elect R. Jones                         119,208,411  62.55  71,381,969     37.45  170,099
 10      Re-elect K. Neirynck                      190,554,413  99.98  36,462         0.02   169,604
 11      Re-elect M. Sutherland                    119,879,952  62.90  70,710,923     37.10  169,604
 12      Appointment of Auditor                    190,656,799  99.95  90,085         0.05   13,595
 13      Remuneration of Auditor                   190,715,105  99.98  32,274         0.02   13,100
 14      Allot shares - general                    119,812,913  62.81  70,933,841     37.19  13,725
 15      Allot shares - additional                 120,008,767  62.92  70,735,963     37.08  15,749
 16      Disapply pre-emption rights - general     119,970,667  62.90  70,776,712     37.10  13,100
 17      Disapply pre-emption rights - additional  119,912,206  62.86  70,835,173     37.14  13,100

The Board notes the votes against Resolutions 2, 9, 11, 14, 15, 16 and 17 and
will consult with shareholders to understand their views and publish the
results of that consultation in due course.

Chris Chrysanthou

Group General Counsel & Company Secretary

29 July 2024

*Each share carries one vote and a 'vote withheld' is not a vote in law and
has not been counted in the calculation of the proportion of the votes for and
against the resolution. Any proxy appointments which gave discretion to the
Chairman have been included in the 'votes for' total.

 

 

 

 

 

For further information:

 

 Alliance Pharma plc                                                       + 44 (0)1249 466966
 Cora McCallum, Head of Investor Relations & Corporate Communications      + 44 (0)1249 705168
 ir@allianceph.com (mailto:ir@allianceph.com)

 Buchanan                                                                  + 44 (0)20 7466 5000
 Mark Court / Sophie Wills
 alliancepharma@buchanan.uk.com (mailto:alliancepharma@buchanan.uk.com)

 Deutsche Numis (Nominated Adviser and Joint Broker)                       + 44 (0)20 7260 1000
 Freddie Barnfield / Duncan Monteith / Sher Shah

 Investec Bank plc (Joint Broker)                                          + 44 (0)20 7597 5970
 Patrick Robb / Ben Lawrence / Maria Gomez de Olea

 

 

About Alliance

 

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our
purpose is to empower people to make a positive difference to their health and
wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and
channels, in related innovation, and through selective geographic expansion to
increase the reach of our brands. Periodically, we may look to enhance our
organic growth through selective, complementary acquisitions.

Headquartered in the UK, the Group employs around 290 people based in
locations across Europe, North America, and the Asia Pacific region. By
outsourcing our manufacturing and logistics we remain asset-light and focused
on maximising the value we can bring, both to our stakeholders and to our
brands.

For more information on Alliance, please visit our
website: www.alliancepharmaceuticals.com
(http://www.alliancepharmaceuticals.com/)

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSESFIUELSEFW